



October 04, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir/Madam,

We refer to our intimation dated July 17, 2025, with respect to the inspection undertaken by U.S. FDA at our Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025, wherein the inspection was closed with the issuance of a Form-483 with four observations.

We would like to update that U.S. FDA has determined the inspection classification of this facility as "Official Action Indicated (OAI)".

The Company is working with the U.S. FDA to satisfactorily resolve the compliance issues and is committed to be compliant with CGMP standards at all its manufacturing facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com